Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

Joaquin Martinez-Lopez, MD PhD, Pau Montesinos, MD PhD, Pilar Martinez Sanchez, Julian Gorrochategui, Jose Luis Rojas, Daniel Primo, PhD, Juan-Miguel Bergua, MD, Rosa M M. Ayala, MD PhD, Maria Calbacho, MD, Nieves López-Muñoz, Evelyn Acuña, MD, Jose Antonio Pérez-Simón, MD, Adolfo de la Fuente, Jaime Perez De Oteyza, MDPhD, Rebeca Rodríguez-Veiga, MD, Blanca Boluda, Isabel Cano, MD, Joan Ballesteros, PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134336

Published: 2020

Journal Articles

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

Cristina De Ramón, Jose Angel Hernandez-Rivas, MD PhD, Jose Antonio Rodríguez García, Enrique M. Ocio, MDPhD, María Teresa Gómez-Casares, MD PhD, Javier López Jiménez, MD PhD, Carlos Solano, MD PhD, Joaquín Martínez-López, Anna Sureda, Manuel Jurado, MD PhD, Raul Córdoba, MD PhD, Celina Benavente, Pascual Marco, Jose Antonio Pérez-Simón, MD, Jose Maria Moraleda, MD PhD, Angela Figuera, Emilia Pardal, Cristina Pascual Izquierdo, PhD MD, Ramon Garcia-Sanz

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142292

Published: 2020

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD PhD, Koji Kato, MD PhD, Hideo Harigae, MD PhD, Marie José Kersten, MD PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz C. Offner, MD PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD, Catherine Thieblemont, MD PhD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138983

Published: 2020

Journal Articles

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Blood (2020) 136 (Supplement 1): 25–27.

https://doi.org/10.1182/blood-2020-141213

Published: 2020

Journal Articles

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Tim Somervaille, MD PhD, Olga Salamero, MD, Pau Montesinos, MD PhD, Christophe Willekens, MD, Jose Antonio Perez Simon, MD, Arnaud Pigneux, MD, Christian Recher, MD PhD, Rakesh Popat, Cesar Molinero, MD PhD, Christina Mascaro, PhD, Tamara Maes, PhD, Francesc Bosch, MD PhD

Blood (2016) 128 (22): 4060.

https://doi.org/10.1182/blood.V128.22.4060.4060

Published: 2016

Journal Articles

Myelomatous Plasma Cells Display An Intermediate Gene Expression Pattern Between a Normal Plasma Cell and a Memory B Cell

Alicia Baez, Jose Ignacio Piruat, Ph.D, Teresa Caballero-Velazquez, María Victoria Barbado, Ph.D, Isabel Alvarez-Laderas, Africa Millan-Ucles, Mayte Medrano, Estefania Garcia-Guerrero, Luis Ignacio Sanchez-Abarca, Ph.D., Ildefonso Espigado, Jose Antonio Perez-Simón, MD, PhD

Blood (2013) 122 (21): 1892.

https://doi.org/10.1182/blood.V122.21.1892.1892

Published: 2013

Journal Articles

The Presence Of 1 / 8 HLA Mismatch Do Not Hamper Survival After Allogeneic Stem Cell Transplantation Using Immunoprophylaxis With Sirolimus-Tacrolimus

Rocío Parody, MD, PhD, Lucía López-Corral, MD, PhD, Oriana Lopez Godino, MD, Irene García Cadenas, Vazquez Lourdes, MD, Rodrigo Martino, MD, PhD, Carmen Martinez, Carlos Solano, Ariadna Perez Martinez, Pere Barba, MD, David Valcarcel, MD, Jose F. Falantes, MD, Francisco J Márquez-Malaver, Dolores Caballero, MD, PhD, Jose Antonio Perez-Simón, MD, PhD

Blood (2013) 122 (21): 4529.

https://doi.org/10.1182/blood.V122.21.4529.4529

Published: 2013

Journal Articles

Memory B Cells Display Changes In The Expression Pattern Of Genes Related To Cell Survival In Elderly Individuals

Alicia Baez, Isabel Alvarez-Laderas, Jose Ignacio Piruat, Ph.D, Teresa Caballero-Velazquez, Africa Millan-Ucles, María Victoria Barbado, Ph.D, Mayte Medrano, Estefania Garcia-Guerrero, Luis Ignacio Sanchez-Abarca, Ph.D., Jose Antonio Perez-Simón, MD, PhD, Ildefonso Espigado

Blood (2013) 122 (21): 4893.

https://doi.org/10.1182/blood.V122.21.4893.4893

Published: 2013

Journal Articles

A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)

Jose Francisco Tomas, MD, PhD, Marcos González, MD, Pilar Giraldo, MD PhD, Mª José Terol, Jose Antonio Pérez Simón, MD, PhD, Raquel de Oña, MD

Blood (2013) 122 (21): 5304.

https://doi.org/10.1182/blood.V122.21.5304.5304

Published: 2013

Journal Articles

Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

Blood (2013) 122 (21): 2754.

https://doi.org/10.1182/blood.V122.21.2754.2754

Published: 2013

Journal Articles

Molecular Dynamics As a Computational Tool To Analyze Lymphocyte Alloreactivity In Hematopoietic Transplant Recipients

Estefania Garcia Guerrero, Irene Diaz Moreno, Miguel Angel De la rosa, Jose Antonio Pérez Simón, MD, PhD, Antonio Diaz Quintana

Blood (2013) 122 (21): 1049.

https://doi.org/10.1182/blood.V122.21.1049.1049

Published: 2013

Journal Articles

Identification Of Patients At High Risk Of Chronic Graft-Versus-Host Disease: Gvhd Prophylaxis

Gabriel Afram, MD, Jose Antonio Pérez Simón, MD, PhD, Mats Remberger, PhD, Teresa Caballero-Velázquez, MD, PhD, Rodrigo Martino, MD, PhD, Jose Luis Piñana, MD, Olle Ringden, MD, Albert Esquirol, MD, Dolores Caballero, MD, PhD, Irene Garcia, MD, Lucía López-Corral, MD, PhD, Jordi Sierra, Oriana López-Godino, Per T. Ljungman, MD, PhD, Jesus F San Miguel, MD, PhD, Hans Hagglund, MD PhD

Blood (2013) 122 (21): 4611.

https://doi.org/10.1182/blood.V122.21.4611.4611

Published: 2013

Journal Articles

Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.

Blood (2007) 110 (11): 729.

https://doi.org/10.1182/blood.V110.11.729.729

Published: 2007

Journal Articles

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Timon Hansen, Georgia Schilling, MD, Peter Liebisch, MD, Rainer Schwerdtfeger, PD, Jose Antonio Perez-Simon, MD, Martin Bornhaeuser, PD, Svenja Otterstetter, Judith Dierlamm, PD, Arnon Nagler, Dieter Kurt Hossfeld, Carsten Bokemeyer, Axel R. Zander, Nicolaus Kroeger, PD

Blood (2006) 108 (11): 5038.

https://doi.org/10.1182/blood.V108.11.5038.5038

Published: 2006

Journal Articles

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Georgia Schilling, MD, Timon Hansen, Jose Antonio Perez-Simon, MD, Rainer Schwerdtfeger, MD, Martin Bornhaeuser, MD, Svenja Otterstetter, Doris Seeger, Judith Dierlamm, PD, Francis Ayuk, MD, Hossfeld Dieter Kurt, Bokemeyer Carsten, Zander R. Axel, Kroeger Nicolaus, PD

Blood (2005) 106 (11): 4338.

https://doi.org/10.1182/blood.V106.11.4338.4338

Published: 2005

NARROW

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Myelomatous Plasma Cells Display An Intermediate Gene Expression Pattern Between a Normal Plasma Cell and a Memory B Cell

The Presence Of 1 / 8 HLA Mismatch Do Not Hamper Survival After Allogeneic Stem Cell Transplantation Using Immunoprophylaxis With Sirolimus-Tacrolimus

Memory B Cells Display Changes In The Expression Pattern Of Genes Related To Cell Survival In Elderly Individuals

A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)

Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

Molecular Dynamics As a Computational Tool To Analyze Lymphocyte Alloreactivity In Hematopoietic Transplant Recipients

Identification Of Patients At High Risk Of Chronic Graft-Versus-Host Disease: Gvhd Prophylaxis

No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.

Deletion of p53 as Detected by Fluorescence In Situ Hybridization Is Associated with Significant Shorter Event-Free Survival in Patients with Multiple Myeloma Who Are Receiving Allogeneic Blood Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only